Somatotropic Axis Dysfunction in Non-Alcoholic Fatty Liver Disease: Beneficial Hepatic and Systemic Effects of Hormone Supplementation
Authors:
- Daniel CabreraDCDaniel Cabrera
- Claudio Cabello-VerrugioCCClaudio Cabello-Verrugio
- Nancy SolísNSNancy Solís
- Diego San MartínDMDiego San Martín
- Catalina CofréCCCatalina Cofré
- Margarita PizarroMPMargarita Pizarro
- Juan Pablo ArabJAJuan Pablo Arab
- Johanna AbrigoJAJohanna Abrigo
- Fabián CamposFCFabián Campos
- Betzabé IrigoyenBIBetzabé Irigoyen
- Gonzalo Carrasco-AvinoGCGonzalo Carrasco-Avino
- Katiuska BezaresKBKatiuska Bezares
Open Access
- 2 May 2018
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (5) , 1339
Abstract
Background: Somatotropic axis dysfunction associated with non-alcoholic fatty liver disease (NAFLD) has potential multisystemic detrimental effects. Here, we analysed the effects of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) supplementation on liver histology, adipokine profile and muscle function in an NAFLD model. Methods: C57BL/6 mice were fed with a high fat diet (HFD) for 12 weeks and were separated into three groups treated for 4 weeks with: (1) High fat diet (HFD) (n = 10); (2) HFD + GH 9 μg/g/d (n = 10); (3) HFD + IGF-1 0.02 µg/g/d (n = 9). A control group fed a chow diet was included (n = 6). Liver histology, liver triglycerides content, serum alanine aminotransferase (ALT) activity, adiponectin and leptin serum levels, in vivo muscle strength, tetanic force and muscle fibre cross-sectional area (CSA) were measured. Results: HFD + GH and HFD + IGF-1 groups showed significantly lower ALT activity compared to HFD (p < 0.01). Liver triglyceride content in HFD + GH was decreased compared to HFD (p < 0.01). Histologic steatosis score was increased in HFD and HFD + GH group (p < 0.01), whereas HFD + IGF-1 presented no difference compared to the chow group (p = 0.3). HFD + GH group presented lower serum leptin and adiponectin levels compared to HFD. GH and IGF-1 supplementation therapy reverted HFD-induced reduction in muscle strength and CSA (sarcopenia). Conclusions: GH and IGF-1 supplementation induced significant improvement in liver steatosis, aminotransferases and sarcopenia in a diet-induced NAFLD model.Keywords
Funding Information
- Fondo Nacional de Desarrollo Científico y Tecnológico (#1150311, 11171001, 1150327, 1161646)
- Instituto Milenio en Inmunología e Inmunoterapia ([P09-016- F])
- Programa de Cooperación Internacional ECOS-Conicyt ([C16S02])
- UNAB-DI ([741-15/N])
This publication has 50 references indexed in Scilit:
- Relationship Between Sarcopenia and Nonalcoholic Fatty Liver Disease: The Korean Sarcopenic Obesity StudyHepatology, 2013
- Measuring the Strength of MiceJournal of Visualized Experiments, 2013
- Non-alcoholic fatty liver disease and insulin resistance: From bench to bedsideDiabetes & Metabolism, 2013
- Metabolic Actions of Insulin-Like Growth Factor-I in Normal Physiology and DiabetesEndocrinology and Metabolism Clinics of North America, 2012
- Growth hormone, insulin-like growth factor 1, and insulin signaling-a pharmacological target in body wasting and cachexiaJournal of Cachexia, Sarcopenia and Muscle, 2011
- Optimal management of sarcopeniaClinical Interventions in Aging, 2010
- The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosisJournal of Endocrinology, 2010
- Adipokines in liver diseases #Hepatology, 2009
- The Role of Liver-Derived Insulin-Like Growth Factor-IEndocrine Reviews, 2009
- Adipocytokines and liver diseaseJournal of Gastroenterology, 2008